.css-1xsl8rf{width:100%;display:-webkit-box;display:-webkit-flex;display:-ms-flexbox;display:flex;-webkit-align-items:center;-webkit-box-align:center;-ms-flex-align:center;align-items:center;position:relative;overflow:hidden;background:var(--alert-bg);-webkit-padding-start:var(--chakra-space-4);padding-inline-start:var(--chakra-space-4);-webkit-padding-end:var(--chakra-space-4);padding-inline-end:var(--chakra-space-4);padding-top:var(--chakra-space-1);padding-bottom:var(--chakra-space-1);--alert-fg:var(--chakra-colors-orange-600);--alert-bg:var(--chakra-colors-orange-100);font-weight:var(--chakra-fontWeights-semibold);padding-left:var(--chakra-space-4);}.chakra-ui-dark .css-1xsl8rf:not([data-theme]),[data-theme=dark] .css-1xsl8rf:not([data-theme]),.css-1xsl8rf[data-theme=dark]{--alert-fg:var(--chakra-colors-orange-200);--alert-bg:rgba(251, 211, 141, 0.16);}@media screen and (min-width: 48em){.css-1xsl8rf{padding-left:var(--chakra-space-8);}}Please enable Javascript to use all features and improve your user experience.

Abstract lecture
A4

Comparison of the primary headache, COVID-19 headache, and COVID-19 immunization headache according to the phenotype in healthcare workers

Appointment

Date: 07 Dec

Time: 13:45 – 13:55

Talk time: 8 Min.

Discussion time: 2 Min.

Location / Stream:

Strauss 2-3

Session

Covid-19 and vaccines related headaches and cluster headache

Topics

COVID and headache
Secondary headaches

Authors

Alicia Gonzalez-Martinez (Madrid/ ES), Paula Paños Basterra (Madrid/ ES), Marta Domínguez Gallego (Madrid/ ES), Alba Somovilla (Madrid/ ES), Carmen Martín Ramos (Madrid/ ES), Álvaro Morales Caballero (Madrid/ ES), Amparo López Guerrero (Madrid/ ES), Manuela García Cebrián (Madrid/ ES), José Vivancos (Madrid/ ES), Ana Beatriz Gago-Veiga (Madrid/ ES)

Abstract

Abstract text (incl. figure legends and references)

Objective: Headache is a frequent symptom during SARS-CoV-2 infection and following COVID-19 immunization. We aimed to characterize the semiology of COVID-19 headache and COVID-19 immunization headache, as well as to evaluate the influence of primary headache-migraine or tension-type headache(TTH)-on the COVID-19 headache and COVID-19 immunization headache phenotype.

Methods: We performed an observational study through an online survey in healthcare workers who had SARS-CoV-2 infection and were included in the Occupational Medicine´s register of our tertiary hospital. Clinical, demographic and headache variables were collected during infection and immunization.

Results: We included 109 participants with COVID-19 headache, 94/109(86,2%) women, 45.1(SD:12.45 years, 24.1(SD:4.3) BMI, 29/109(26.6%) cardiovascular risk factors, 15/112(13.39%) 15/109(13.8%) anxiety, 7/109(6.4%) depression, 22/109(20.18%) migraine as primary headache, 11/109(10,09%) TTH as primary headache. COVID-19 headache was the first symptom in 24/109(22%), appeared in

Conclusions: According to our study, both COVID-19 headache and COVID-19 immunization headache frequently follow a TTH-like phenotype more than a migraine phenotype. Moreover, COVID-19 immunization headache is frequently more similar to the COVID-19 headache than to the primary headache.